Investing in Outset Medical Inc. (OM) is a safe bet with a significant edge

In the latest session, Outset Medical Inc. (NASDAQ: OM) closed at $28.11 up 3.35% from its previous closing price of $27.20. In other words, the price has increased by $+0.91 from its previous closing price. On the day, 782072 shares were traded. OM stock price reached its highest trading level at $29.61 during the session, while it also had its lowest trading level at $26.64.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Ratios:

For a deeper understanding of Outset Medical Inc.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.10 and its Current Ratio is at 6.20. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.11.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, RBC Capital Mkts on November 11, 2022, initiated with a Outperform rating and assigned the stock a target price of $23.

On July 14, 2022, Morgan Stanley Downgraded its rating to Equal-Weight which previously was Overweight and also lowered its target price recommendation from $48 to $20.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 03 when Trigg Leslie sold 30,000 shares for $25.26 per share. The transaction valued at 757,728 led to the insider holds 290,243 shares of the business.

Vazquez Martin sold 5,000 shares of OM for $130,716 on Jan 03. The Chief Operating Officer now owns 49,290 shares after completing the transaction at $26.14 per share. On Dec 01, another insider, Vazquez Martin, who serves as the Chief Operating Officer of the company, sold 5,000 shares for $20.85 each. As a result, the insider received 104,250 and left with 49,290 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 12.15 while its Price-to-Book (P/B) ratio in mrq is 4.85.

Stock Price History:

Over the past 52 weeks, OM has reached a high of $48.71, while it has fallen to a 52-week low of $11.41. The 50-Day Moving Average of the stock is 23.17, while the 200-Day Moving Average is calculated to be 21.67.

Shares Statistics:

For the past three months, OM has traded an average of 556.22K shares per day and 477.23k over the past ten days. A total of 48.13M shares are outstanding, with a floating share count of 47.91M. Shares short for OM as of Oct 13, 2022 were 4.73M with a Short Ratio of 3.86M, compared to 4.49M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 9.85% and a Short% of Float of 11.62%.

Earnings Estimates

There are 5 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.81 for the current quarter, with a high estimate of -$0.67 and a low estimate of -$0.91, while EPS last year was -$0.65. The consensus estimate for the next quarter is -$0.72, with high estimates of -$0.57 and low estimates of -$0.86.

Analysts are recommending an EPS of between -$3.22 and -$3.43 for the fiscal current year, implying an average EPS of -$3.32. EPS for the following year is -$2.31, with 5 analysts recommending between -$1.85 and -$2.62.

Revenue Estimates

A total of 6 analysts have provided revenue estimates for OM’s current fiscal year. The highest revenue estimate was $109.6M, while the lowest revenue estimate was $107.45M, resulting in an average revenue estimate of $108M. In the same quarter a year ago, actual revenue was $102.6M, up 5.30% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $157.14M in the next fiscal year. The high estimate is $166.8M and the low estimate is $145.91M. The average revenue growth estimate for next year is up 45.50% from the average revenue estimate for this year.